[1] Mormone E, George J, Nieto N.Molecular pathogenesis of hep-atic fibrosis and current therapeutic approaches.Chem BiolInteract, 2011, 193: 225-231.
[2] Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest, 2007, 117: 524-529.
[3] Liu C, Chen X, Yang L,et al. Transcriptional repression of the transforming growth factor b (TGF-b) Pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) by Nuclear Factor jB (NFjB) p50 enhances TGF-b signaling in hepatic stellate cells. J Biol Chem, 2014, 289: 7082-7091.
[4] Ge PS, Runyon BA.Treatment of patients with cirrhosis.N Engl J Med, 2016, 375: 767-777.
[5] Chang TT, Liaw YF, Wu SS, et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology, 2010, 52: 886-993.
[6] Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, et al.Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. Mater Sociomed, 2014, 26: 172-176.
[7] Miranda-Mendez A, Lugo-Baruqui A, Armendariz-Borunda J.Molecular basis and current treatment for alcoholic liver dis-ease.Int J Environ Res Public Health, 2010, 7: 1872-1888.
[8] 顾立飞, 汪余勤, 段晓燕, 等.Lemmel综合征合并自身免疫性肝炎1例.实用医学杂志, 2015, 31: 2593.
[9] 郭锐, 覃进.随机对照试验研究UDCA治疗原发性胆汁性肝硬化患者的疗效及安全性.实用肝脏病杂志, 2017, 20: 109-110.
[10] Lakner AM,Steuerwald NM,Walling TL,et al.Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis.Hepatology,2012,56:300-310.
[11] Yin C, Evason KJ, Asahina K, et al. Hepatic stellate cells in liver development, regeneration, and cancer. The Journal of clinical investigation, 2013, 123: 1902-1910.
[12] Troeger JS, Mederacke I, Gwak GY, et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology, 2012, 143:1073-1083, e22.
[13] Qin W, Chung AC, Huang XR, et al. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol, 2011, 22: 1462-1474.
[14] Xiao J, Meng XM, Huang XR, et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther, 2012, 20: 1251-1260.
[15] Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol, 2011, 25: 195-206.
[16] Sanchez-Valle V, Chavez-Tapia NC, Uribe M. et al.Role of oxidative stress and molecular changes in liver fibrosis: A review Curr Med Chem, 2012, 19: 4850-4860.
[17] Cichoz-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J. Gastroenterol, 2014, 20: 8082-8091.
[18] Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int, 2011, 31: 1432-1448.
[19] Esrefoglu M. Oxidative stress and benefits of antioxidant agents in acute and chronic hepatitis. Hepat Mon, 2012, 12: 160-167.
[20] Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment Cell, 2010, 141: 52-67
[21] Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion Semin Cancer Biol, 2010, 20: 161-168
[22] Calabro SR, Maczurek AE, Morgan AJ, et al. Hepatocyte produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis PLoS One, 2014, 9: e90571
[23] Berardis S, Lombard C, Evraerts J, et al. Gene expression profiling and secretome analysis differentiate adult-derived human liver stem/progenitor cells and human hepatic stellate cells. PLoS One, 2014, 9: e86137.
[24] Li T, Yan Y, Wang B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev, 2013, 22: 845-854.
[25] 赖文芳, 吴符火, 陈兴明.丹参抗肝纤维化作用机制的研究进展.中国民族民间医药, 2010, 3:30-32.
[26] 张晓平, 陈建明, 强世平, 等.山桃仁水煎提取物对肝纤维化小鼠血清Ⅰ、Ⅲ型前胶原的降解作用.福建中医药, 2002, 33: 36-37.
[27] 王书明.中药治疗慢性乙型肝炎临床疗效分析.中国中医药现代远程教育, 2014, 12: 32-33.
[28] 赵景民,周光德,李文淑,等.复方鳖甲软肝片抗肝纤维化机制的实验研究.解放军医学杂志,2004,29: 560-562.
[29] 徐微.替比夫定联合扶正化瘀胶囊对慢性乙型肝炎肝纤维化患者的疗效观察.肝脏, 2013, 18: 654-655. |
